Literature DB >> 21422315

The role of MAGEA2 in head and neck cancer.

Chad A Glazer1, Ian M Smith, Sheetal Bhan, Wenyue Sun, Steven S Chang, Kavita M Pattani, William Westra, Zubair Khan, Joseph A Califano.   

Abstract

OBJECTIVE: To examine the role of MAGEA2 in the tumorigenesis of head and neck squamous cell carcinoma (HNSCC).
DESIGN: Primary tissue microarray data and quantitative reverse transcription-polymerase chain reaction (RT-PCR) showed that MAGEA2 is differentially overexpressed in HNSCC. Functional analyses were then performed using MAGEA2 transfections and small-interfering RNA knockdowns with subsequent anchorage-dependent growth studies and cell cycle analyses. Quantitative RT-PCR was used to evaluate expression changes in p53 downstream targets after transfection of MAGEA2 into normal upper aerodigestive cell lines.
RESULTS: MAGEA2 is differentially overexpressed in HNSCC. In addition, MAGEA2 promotes growth in normal oral keratinocytes, whereas knockdown of MAGEA2 in HNSCC cells decreases growth. Using the HCT116 p53 wt and null cell line system, transfection of MAGEA2 induced growth in the p53 wt cell line while providing no growth advantage in the p53 mutant cells. Subsequently, transfection of MAGEA2 induced a decrease in messenger RNA expression of the p53 downstream targets CDKN1A and BAX and decreased G1 arrest in cells allowed to remain confluent for longer than 48 hours.
CONCLUSIONS: These data suggest that MAGEA2 is differentially expressed in HNSCC and functions, in part, through the p53 pathway by increasing cellular proliferation and abrogating cell cycle arrest. This improved understanding of MAGEA2 function and expression patterns will potentially allow for the improved ability to use MAGEA2 for detection, surveillance, and targeted therapeutics.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21422315      PMCID: PMC3309612          DOI: 10.1001/archoto.2011.2

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  38 in total

1.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Authors:  Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan
Journal:  Science       Date:  2005-10-28       Impact factor: 47.728

Review 2.  The p53 tumor suppressor participates in multiple cell cycle checkpoints.

Authors:  Luciana E Giono; James J Manfredi
Journal:  J Cell Physiol       Date:  2006-10       Impact factor: 6.384

3.  MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents.

Authors:  Martin Monte; Marta Simonatto; Leticia Y Peche; Debora R Bublik; Stefania Gobessi; Marco A Pierotti; Monica Rodolfo; Claudio Schneider
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-17       Impact factor: 11.205

Review 4.  Cancer/testis antigens, gametogenesis and cancer.

Authors:  Andrew J G Simpson; Otavia L Caballero; Achim Jungbluth; Yao-Tseng Chen; Lloyd J Old
Journal:  Nat Rev Cancer       Date:  2005-08       Impact factor: 60.716

5.  Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response.

Authors:  Olga Aprelikova; Silvia Pandolfi; Sean Tackett; Mark Ferreira; Konstantin Salnikow; Yvona Ward; John I Risinger; J Carl Barrett; John Niederhuber
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

6.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

7.  TP53 mutations and survival in squamous-cell carcinoma of the head and neck.

Authors:  M Luana Poeta; Judith Manola; Meredith A Goldwasser; Arlene Forastiere; Nicole Benoit; Joseph A Califano; John A Ridge; Jarrard Goodwin; Daniel Kenady; John Saunders; William Westra; David Sidransky; Wayne M Koch
Journal:  N Engl J Med       Date:  2007-12-20       Impact factor: 91.245

8.  Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma.

Authors:  André Lopes Carvalho; Carmen Jeronimo; Michael M Kim; Rui Henrique; Zhe Zhang; Mohammad O Hoque; Steve Chang; Mariana Brait; Chetan S Nayak; Wei-Wen Jiang; Quia Claybourne; Yutaka Tokumaru; Juna Lee; David Goldenberg; Elizabeth Garrett-Mayer; Steven Goodman; Chul-so Moon; Wayne Koch; William H Westra; David Sidransky; Joseph A Califano
Journal:  Clin Cancer Res       Date:  2008-01-01       Impact factor: 12.531

9.  Expression of melanoma-associated antigens in oral squamous cell carcinoma.

Authors:  Jutta Ries; Eleftherios Vairaktaris; Nur Mollaoglu; Joerg Wiltfang; Friedrich W Neukam; Emeka Nkenke
Journal:  J Oral Pathol Med       Date:  2008-02       Impact factor: 4.253

10.  Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer.

Authors:  Ian M Smith; Chad A Glazer; Suhail K Mithani; Michael F Ochs; Wenyue Sun; Sheetal Bhan; Alexander Vostrov; Ziedulla Abdullaev; Victor Lobanenkov; Andrew Gray; Chunyan Liu; Steven S Chang; Kimberly L Ostrow; William H Westra; Shahnaz Begum; Mousumi Dhara; Joseph Califano
Journal:  PLoS One       Date:  2009-03-23       Impact factor: 3.240

View more
  9 in total

1.  [Immunotherapy of head and neck cancer. Current developments].

Authors:  P J Schuler; T K Hoffmann; T C Gauler; C Bergmann; S Brandau; S Lang
Journal:  HNO       Date:  2013-07       Impact factor: 1.284

2.  MAGE-A1-6   expression in patients with head and neck squamous cell carcinoma: impact on clinical patterns and oncologic outcomes.

Authors:  Sang Tae Noh; Hyoung Shin Lee; Soo Jin Lim; Sung Won Kim; Hee Kyung Chang; Junghwan Oh; Chang-Ho Jeon; Jong Wook Park; Kang Dae Lee
Journal:  Int J Clin Oncol       Date:  2016-05-26       Impact factor: 3.402

3.  Overexpression of melanoma-associated antigen A2 has a clinical significance in embryonal carcinoma and is associated with tumor progression.

Authors:  Leili Saeednejad Zanjani; Monireh Mohsenzadegan; Mahdieh Razmi; Fahimeh Fattahi; Elham Kalantari; Maryam Abolhasani; Sima Saki; Zahra Madjd
Journal:  J Cancer Res Clin Oncol       Date:  2021-11-27       Impact factor: 4.553

Review 4.  Deciphering the Role of the Barr Body in Malignancy: An insight into head and neck cancer.

Authors:  Deepti Sharma; George Koshy; Shruti Gupta; Bhushan Sharma; Sonal Grover
Journal:  Sultan Qaboos Univ Med J       Date:  2018-01-10

5.  hMAGEA2 promotes progression of breast cancer by regulating Akt and Erk1/2 pathways.

Authors:  Song Park; Yonghun Sung; Jain Jeong; Minjee Choi; Jinhee Lee; Wookbong Kwon; Soyoung Jang; Si Jun Park; Hyeng-Soo Kim; Mee-Hyun Lee; Dong Joon Kim; Kangdong Liu; Sung-Hyun Kim; Zigang Dong; Zae Young Ryoo; Myoung Ok Kim
Journal:  Oncotarget       Date:  2017-06-06

6.  Expression of MAGE-A and NY-ESO-1 cancer/testis antigens is enriched in triple-negative invasive breast cancers.

Authors:  Ashwini Raghavendra; Priyakshi Kalita-de Croft; Ana C Vargas; Chanel E Smart; Peter T Simpson; Jodi M Saunus; Sunil R Lakhani
Journal:  Histopathology       Date:  2018-04-14       Impact factor: 5.087

Review 7.  Role and Clinical Utility of Cancer/Testis Antigens in Head and Neck Squamous Cell Carcinoma.

Authors:  Sharon Changshan Wu; Karl Münger
Journal:  Cancers (Basel)       Date:  2021-11-14       Impact factor: 6.639

8.  Consequences of point mutations in melanoma-associated antigen 4 (MAGE-A4) protein: Insights from structural and biophysical studies.

Authors:  Yoshio Hagiwara; Lina Sieverling; Farina Hanif; Jensy Anton; Eleanor R Dickinson; Tam T T Bui; Antonina Andreeva; Perdita E Barran; Ernesto Cota; Penka V Nikolova
Journal:  Sci Rep       Date:  2016-04-28       Impact factor: 4.379

9.  Signature microRNAs and long noncoding RNAs in laryngeal cancer recurrence identified using a competing endogenous RNA network.

Authors:  Zhengyi Tang; Ganguan Wei; Longcheng Zhang; Zhiwen Xu
Journal:  Mol Med Rep       Date:  2019-04-10       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.